OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 13:26:47 01/07/2024 BST | ||
| 2.1 EUR | +37.25% |
|
| Current month | -59.20% | ||
| 1 month | -61.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 2.1 | +37.25% |
| 28/06/24 | 1.53 | -4.97% |
| 27/06/24 | 1.61 | +0.63% |
| 26/06/24 | 1.6 | -4.76% |
| 25/06/24 | 1.68 | +18.31% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 01:26 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG15Y0 |
| ISIN | DE000GG15Y01 |
| Date issued | 15/12/2023 |
| Strike | 489.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.43 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.22 € |
|---|---|
| Lowest since issue | 0.674 € |
| Spread | 0.1 € |
| Spread % | 6.76% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
